Home › Funds › Defilade Capital Management, L.P. › EVMN
Defilade Capital Management, L.P. position in EVMN
EVOMMUNE INC · Health Care
Defilade Capital Management, L.P. reported holding 793,145 shares of EVMN (EVOMMUNE INC) in its Q2 2026 13F filing — a position valued at US$10.5M, representing 1.41% of its reported portfolio and ranking #30 among its reported holdings. Defilade Capital Management, L.P. has disclosed EVMN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s EVMN position evolved
Defilade Capital Management, L.P. first disclosed a stake in EVMN in Q4 2025 at 215,418 shares (US$3.7M). The position peaked in Q1 2026 at 678,589 shares, worth US$15.6M. Across 3 filings, Defilade Capital Management, L.P. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 793,145 shares valued at US$10.5M — an increase of 114,556 shares quarter over quarter.. Notable position changes include a 215% increase in Q1 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 215.42K | $3.69M | New |
| Q1 2026 | 678.59K | $15.60M | Add |
| Q2 2026 | 793.14K | $10.54M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 116 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$70.3M), RA CAPITAL MANAGEMENT, L.P. (US$46.4M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- EQT Fund Management S.a r.l. 5.29M sh · $70.28M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $46.44M · Q2 2026
- SymBiosis Capital Partners, LLC 1.28M sh · $29.45M · Q1 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $25.61M · Q2 2026
- Nan Fung Group Holdings Ltd 1.44M sh · $19.15M · Q2 2026
- Velan Capital Investment Management LP 451.25K sh · $6.00M · Q2 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $4.32M · Q2 2026
- Blue Owl Capital Holdings LP 180.00K sh · $2.39M · Q2 2026
- NEXTBio Capital Management LP 119.06K sh · $1.58M · Q2 2026
- Avidity Partners Management LP 75.00K sh · $996.75K · Q2 2026
- Andera Partners 97.36K sh · $804.21K · Q3 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held EVMN?
Defilade Capital Management, L.P. has disclosed EVMN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in EVMN?
As of Q2 2026, Defilade Capital Management, L.P. holds 793.14K shares of EVMN (EVOMMUNE INC), valued at $10.54M, representing 1.41% of its reported portfolio and ranking #30.
Has Defilade Capital Management, L.P. been buying or selling EVMN?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in EVMN. The position peaked in Q1 2026 at 678.59K shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., SymBiosis Capital Partners, LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.